Both I and my girlfriend, have children from previous relationships. But still, one child is not enough. It doesnt feel like I got enough enjoyment with children. And I think its good to have children because somebody needs to take over in the future, Smigrodzki said. So, between my girlfriend and I, we decided to have a child.
Due to his girlfriends age, one of the couples only options was IVF.
Smigrodzki was interested in also using the tests offered by Genomic Prediction. They met with an IVF doctor in Charlotte, North Carolina. Since the testing was new, the company sent a scientist to explain the technology to the doctors on the IVF team.
During the next visit, our physician told us that they would not let us use the technology, because that [would be] unethical.
Smigrodzki disagreed with the doctors decision.
A physician who tells you that they will not use a life and health-saving technology because its unethical is a physician who is making a big mistake. Theres absolutely no credible reasoning that would justify this kind of a decision, Smigrodzki said.
This wouldnt be the last time Genomic Prediction caused tension. Controversy and resistance seem to follow the company.
Stephen Hsu, a co-founder of Genomic Prediction, said he became interested in computational genomics about 10 years ago.
It became possible to build predictors using machine learning and artificial intelligence, which would look directly at the DNA of an individual and could tell whether someone was at unusually high risk, for example, for a specific disease condition. When we started seeing how powerful these techniques were, we realized one of the most obvious applications of it would be in embryo selection, Hsu said.
IVF clinics have long tested embryos for genetic diseases. But what differentiates Genomic Prediction from routine genetic testing is the companys promise to give an overall health impression of an embryo not just testing to see if it has a specific disease or not.
This is much more complicated than screening, say, for Huntingtons disease. A single gene causes that disease, and tests for Huntingtons disease have a 99.9% accuracy rate. But test results for complex conditions, meaning they involve many, even thousands of genes, like heart disease or diabetes, are much less precise. So instead of giving definitive results, Genomic Prediction provides a risk score an estimate of how likely an embryo will be to develop a disease.
One very common case, which weve seen many times already, is a couple comes in and they know they have a family history of x. And just to take a concrete example, x could be breast cancer. So it could be that in the mothers family tree, there are women that had breast cancer, said Hsu.
And they may just say, Look, I saw my aunt die from breast cancer, and I just dont want it to happen to my daughter. So, I just want to make sure that of the embryos we look at, I want the one we implant to be normal risk, not high risk.'
Testing for breast cancer risk may not sound all that controversial. But you could imagine where this could go.
Remember that Smigrodzkis first IVF doctors refused to administer the test, calling it unethical.
To start, the same technology that can test for complex diseases can also test for things like eye color, skin tone, or height.
So, the accuracy with which one can predict height, from DNA alone, for people who have good family environments, you know, growing up, the error is less than three centimeters now, Hsu said.
That means the scientists at Genomic Prediction say theyre able to predict adult height within a bit more than an inch before you are even born. But they are not doing that yet.
We only provide risk scores for very impactful common diseases. Because its just too controversial, people just get too excited, Hsu said. We can make predictions about IQ scores of individuals. But we do not provide any of that information in our IVF service, just because its too controversial.
But what about traits that fall somewhere in the middle of eye color and disease risk?
We can predict BMI [body mass index], Hsu said. And theres a whole complex of health problems that come with being significantly overweight. Now, are we going to report BMI prediction scores? Would people call us fat shaming if we did that? As you know, its extremely delicate.
Hsu and his company are pioneers with this type of genetic testing. They are making choices on what diseases and traits to test for, how accurate the tests should be, and if they should even offer the test. And the work they are doing will influence the direction this industry takes.
There are guidelines from the American Society for Reproductive Medicine. And those guidelines support the use of this kind of technology to prevent disease, they do not explicitly support the use of this kind of technology for cosmetic purposes, and they dont really talk about IQ, Hsu said.
So, its kind of a gray area. Were certainly not forbidden from doing it, but we just chose not to do it. Because from our perspective, theres so much good that you can do just on the purely medical health risk front, that we dont want that to get drowned out by this other stuff.
Hsu never explicitly said where he draws the line. But he did say that people should have a better understanding of these tests.
People should become aware of how the technology works, how does heredity work, how the genes work people should learn that. And then, through a kind of democratic process, they should decide this is the kind of society we want to be. This is what we should allow. We like gene editing, we dont like gene editing, we like embryo selection, we dont, he said.
He says this technology, the ability to screen embryos for diseases and even non-disease traits, is becoming more sophisticated, and more importantly, it is becoming more available. There are other companies that plan to offer similar testing.
Even though Genomic Prediction doesnt offer scores based on intelligence, a recent article in Bloomberg follows a couples journey with embryo selection. The couple used Genomic Prediction and wanted more data than the company offers, so they downloaded the raw embryo data. They analyzed it to weigh the odds of mental health traits, like stress management and chronically low mood. They told Bloomberg that what was most important to them was mental health and performance.
As this genetic modeling continues to improve and become more wide-spread, we must start asking the hard questions: How will we use it?
Laura Hercher, director of research in human genetics at Sarah Lawrence College in Bronxville, New York, says almost everything to do with embryos and manipulation of embryos stirs up some controversy.
Hercher is a trained clinical genetic counselor, licensed to work with patients. But lately, she spends her time educating on ethical, legal, and social issues in genomic medicine. She says these test results are much more nuanced than they may seem.
Ive talked to a lot of genetic counselors about embryo testing. And mostly we have a good laugh. I always say if I was going to write a textbook on genetics which, God forbid I would entitle it, It Turned Out to be More Complicated Than They Thought.'
One of the biggest challenges with these risk scores is that scientists simply dont know all of the genes involved with complex conditions like heart disease or cancer.
Another problem is that the information scientists do have comes from genetic databases with overwhelming white, European participants. Applying that data to other populations, some scientists say, is misleading.
Its population data, which means that you have to be very careful about how you use it for an individual, Hercher said.
These genetic tests say something about your risk, the way your zip code, when youre born says something about your risk. If we calculated it over a population, and said, whats your chance of going to college based on the zip code you were born in? We could trace a relationship, right? Thats intuitive. But it would not be causal it would not be the end point.
So, the tests arent perfect. But they will continue to improve. Already, parents who use IVF can select an embryo based on its biological sex, which is not a concerning medical condition. They can also screen embryos for rare, devastating disorders like Huntingtons disease. But soon, testing could include conditions that may or may not be considered a serious medical concern.
Hercher said, take ADHD or autism, for example.
People might fear these conditions, they might particularly fear them based on sort of worst-case scenario thinking, that it can get very bad. But also, these are medical labels we have applied in some cases, to things that were well within the spectrum of, really normal behavior, said Hercher. And I think globally, big picture, when people look at the use of these technologies with embryos, one of their fears has to have something to do about reducing our vision of what is normal and acceptable in the human population. And specifically doing that, for people who can pay for it.
Stephen Hsu from Genomic Prediction said that his company was starting to see inquiries from couples interested in doing IVF just so they could do the embryo selection process. Couples tell him:
Hey, we heard about this, and it just seems like such a smart thing to do. Were actually considering doing IVF. Because we can get a better health outcome for our children, even though were not necessarily having fertility issues, Hsu said.
IFV is already very expensive, and the additional genetic test itself is about $2,000 per cycle. Hercher warns that we must be careful about how this difference in access will impact society.
So, how do you draw the actual lines there? I think the only way to do it is to try and bring the population along with you, Hercher said, to try and explain the limitations of the genetics and explain the negative effects of too much selection and too much trying to control what a child is like.
With all of that in place, Hercher said she doesnt, see an option other than to trust parents to make decent decisions.
Fundamentally, one reason why we dont want to get into selection of things that are less like diseases and more like traits, she added, is that what we owe our children above everything else, is to accept them and love them as they are.
Rafal Smigrodzki says it was his sense of fatherly responsibility that influenced his decision.
You see, its all about the children. Its not about us, right? Smigrodzki said. He said he expects that children would be grateful if parents choose certain traits for them, like intelligence.
Intelligence is a good, Smigrodzki said Its not a weapon that we use against each other in a fight. Its actually something that we use to understand and control the world. And its precisely our intelligence that gives us the ability to progress to build civilization. So, theres absolutely nothing wrong, in my opinion, in selecting an embryo based on intelligence.
For Smigrodzki and his girlfriend, they ultimately found an IVF provider in Washington D.C. that was willing to work with Genomic Prediction. They started with 16 embryos and eventually had five surviving embryos genetically tested.
Out of the remaining five, one had a chromosomal abnormality, so it was immediately rejected. And out of the four remaining ones Genomic Prediction provided a list of odds for different conditions, including cancer, diabetes, hypertension, and cardiovascular disease, he said.
Its up to the parents to decide how to weigh those odds. Smigrodzki decided to select the embryo with the lowest risk of heart disease. Later, Genomic Prediction came up with an overall, embryonic health score, taking into account each possible condition, the odds, and the potential for a higher quality of life. Smigrodzki later had those embryonic health scores calculated for the four embryos he had to choose from.
The embryo that became Aurea [had] by far the best health score of the four of them. So, it means that I could congratulate myself because I selected the best embryo.
See the rest here:
Startup offers genetic testing that promises to predict healthiest embryo - WHYY
- BENITEC BIOPHARMA INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) - Marketscreener.com - February 13th, 2023 [February 13th, 2023]
- CENTOGENE to Participate in Upcoming Conferences in February in the Lead Up to Rare Disease Day - Marketscreener.com - February 7th, 2023 [February 7th, 2023]
- Gene | Definition, Structure, Expression, & Facts | Britannica - January 27th, 2023 [January 27th, 2023]
- New gene therapy delivers treatment directly to brain - January 27th, 2023 [January 27th, 2023]
- Indian Pharma Congress: Gene-cell therapy, preventive medicine future of health care, says expert - Economic Times - January 25th, 2023 [January 25th, 2023]
- A blood test that identifies people at higher risk of miscarriage? Thats the goal of this award-winning Rutgers med student. - The Philadelphia... - January 19th, 2023 [January 19th, 2023]
- Gene Therapy: Genes As Medicine | Pfizer - January 6th, 2023 [January 6th, 2023]
- How Genomics will ensure a risk-free and beneficial treatment for good health and well-being - The Financial Express - December 28th, 2022 [December 28th, 2022]
- Regenerative Medicine Advanced Therapy Designation | FDA - December 18th, 2022 [December 18th, 2022]
- 3576 - Gene ResultCXCL8 C-X-C motif chemokine ligand 8 [ (human)] - November 23rd, 2022 [November 23rd, 2022]
- Study identifies new gene that drives colon cancer - EurekAlert - October 17th, 2022 [October 17th, 2022]
- Updated Stroke Gene Panels: Rapid evolution of knowledge on monogenic causes of stroke | European Journal of Human Genetics - Nature.com - October 17th, 2022 [October 17th, 2022]
- The challenges of translating CRISPR to the clinic - Labiotech.eu - October 17th, 2022 [October 17th, 2022]
- Editas Medicine Presents Preclinical Data on EDIT-103 for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa at the European Society of Gene... - October 17th, 2022 [October 17th, 2022]
- 'We have to find a way': FDA seeks solutions to aid bespoke gene therapy - BioPharma Dive - October 17th, 2022 [October 17th, 2022]
- Mathematical model could bring us closer to effective stem cell therapies - Michigan Medicine - October 17th, 2022 [October 17th, 2022]
- Approval, Commercialization Highlighted at Cell & Gene Meeting on the Mesa - Genetic Engineering & Biotechnology News - October 17th, 2022 [October 17th, 2022]
- CANbridge-UMass Chan Medical School Gene Therapy Research in Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 29th Annual... - October 17th, 2022 [October 17th, 2022]
- Depression Treatment: How Genetic Testing Can Help Find the Right Medication - Dunya News - October 17th, 2022 [October 17th, 2022]
- The Risk-Reward Proposition for CGT Clinical Trials - Applied Clinical Trials Online - October 17th, 2022 [October 17th, 2022]
- Precision Medicine Could Get Even More Precise With Allarity Therapeutics Next-Generation Diagnostics - Benzinga - October 17th, 2022 [October 17th, 2022]
- Decibel Therapeutics Receives FDA Clearance of IND Application for DB-OTO, a Gene Therapy Product Candidate Designed to Provide Hearing to Individuals... - October 17th, 2022 [October 17th, 2022]
- Time for your medicine: unlocking the power of our body clocks - The Guardian - October 17th, 2022 [October 17th, 2022]
- Replay establishes distinguished Scientific Advisory Board of genomic medicine and cell therapy experts - Yahoo Finance - October 17th, 2022 [October 17th, 2022]
- Scientists Reappraise the Role of Zombie Cells That Anti-aging Medicine Has Sought to Eliminate - Neuroscience News - October 17th, 2022 [October 17th, 2022]
- Forge Biologics Announces Updated Positive Clinical Data in RESKUE, a Novel Phase 1/2 Gene Therapy Trial for Patients with Krabbe Disease - Business... - October 17th, 2022 [October 17th, 2022]
- Gene Expression Signatures Are Analyzed for Biomarkers of Response in HCC - Targeted Oncology - October 17th, 2022 [October 17th, 2022]
- NHS England World-first national genetic testing service to deliver rapid life-saving checks for babies and kids - NHS England - October 17th, 2022 [October 17th, 2022]
- The proteinprotein relationship that could mend a broken heart - RegMedNet - October 17th, 2022 [October 17th, 2022]
- Study finds microprotein correlated to Alzheimers risk - Daily Trojan Online - October 11th, 2022 [October 11th, 2022]
- Passage Bio Announces Appointment of William Chou, M.D. as Chief Executive Officer - Yahoo Finance - October 11th, 2022 [October 11th, 2022]
- Gene Therapy Rapidly Improves Night Vision in Adults with Congenital Blindness - Newswise - October 11th, 2022 [October 11th, 2022]
- Scientists Discover Protein Partners that Could Heal Heart Muscle | Newsroom - UNC Health and UNC School of Medicine - October 11th, 2022 [October 11th, 2022]
- The Pros and Cons of Lentiviral and Adeno-Associated Viral Vectors - The Medicine Maker - October 11th, 2022 [October 11th, 2022]
- Insights & Outcomes: Foreign DNA, quantum potholes and relapsing fever - Yale News - October 11th, 2022 [October 11th, 2022]
- Expediting IND applications with drug master files - BioPharma Dive - October 11th, 2022 [October 11th, 2022]
- UNC School of Medicine Awarded $3 Million to Lead Study to Reduce PTSD Frequency, Severity | Newsroom - UNC Health and UNC School of Medicine - October 11th, 2022 [October 11th, 2022]
- Lineage to Present at Alliance for Regenerative Medicine 2022 Cell & Gene Meeting on the Mesa - businesswire.com - October 8th, 2022 [October 8th, 2022]
- The Next Crispr Gene Editing IPO Could Be Near - Henry Herald - October 8th, 2022 [October 8th, 2022]
- 10-year CRISPR anniversary: How gene editing revolutionized medicine, and what lies ahead - Genetic Literacy Project - October 8th, 2022 [October 8th, 2022]
- Blood from a baby at birth can be gene sequenced to prevent diseases - USA TODAY - October 8th, 2022 [October 8th, 2022]
- What doctors wish patients knew about breast-cancer prevention - American Medical Association - October 8th, 2022 [October 8th, 2022]
- Growth in Cell and Gene Therapy Market - Pharmaceutical Technology Magazine - October 8th, 2022 [October 8th, 2022]
- Gene Editing Service Market 2022 : Top Players to Reflect Impressive Growth Rate till 2029: Caribou Biosciences, CRISPR Therapeutics, Merck KGaA,... - October 8th, 2022 [October 8th, 2022]
- Tip Sheet: $78 million to support new precision oncology institute, update on experimental gene therapy for herpes and the launch of Fred Hutch's new... - October 8th, 2022 [October 8th, 2022]
- Cell and Gene Therapy: Rewriting the Future of Medicine - Technology Networks - October 2nd, 2022 [October 2nd, 2022]
- Growth in Cell and Gene Therapy Market - BioPharm International - October 2nd, 2022 [October 2nd, 2022]
- CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX130 for the Treatment of Cutaneous T-Cell... - October 2nd, 2022 [October 2nd, 2022]
- BioMarin Resubmits Biologics License Application (BLA) for Valoctocogene Roxaparvovec AAV Gene Therapy for Severe Hemophilia A to the FDA - PR... - October 2nd, 2022 [October 2nd, 2022]
- Fighting Breast and Ovarian Cancer With a Lupus Antibody - Yale School of Medicine - October 2nd, 2022 [October 2nd, 2022]
- This gene therapy company is testing new tech to 'switch off' diabetes and obesity with a pill - Euronews - October 2nd, 2022 [October 2nd, 2022]
- Tenaya Therapeutics to Participate in Inaugural Hypertrophic Cardiomyopathy Medical Societys 2022 Scientific Sessions - Yahoo Finance - October 2nd, 2022 [October 2nd, 2022]
- Risk of Alzheimer's dementia may be predicted with help of new tool Washington University School of Medicine in St. Louis - Washington University... - October 2nd, 2022 [October 2nd, 2022]
- Tiny Sea Creature's Genes Shed Light on Evolution of Immunity - UPMC - October 2nd, 2022 [October 2nd, 2022]
- Who will get the call from Stockholm? It's time for STAT's 2022 Nobel Prize predictions - STAT - October 2nd, 2022 [October 2nd, 2022]
- Excision BioTherapeutics Awarded California Institute for Regenerative Medicine (CIRM) Grant to Support Ongoing Phase 1/2 Trial Evaluating EBT-101 as... - October 2nd, 2022 [October 2nd, 2022]
- NeuroVoices: Emma Ciafaloni, MD, on the Vast Expansion of Innovative Approaches to Duchenne Muscular Dystrophy - Neurology Live - October 2nd, 2022 [October 2nd, 2022]
- COVID mRNA Jabs and Testing Kicked Off This Industry of Drug Development: Here's What You Need to Know - The Epoch Times - October 2nd, 2022 [October 2nd, 2022]
- Kidney resident macrophages have distinct subpopulations and occupy distinct microenvironments - University of Alabama at Birmingham - October 2nd, 2022 [October 2nd, 2022]
- Nobel Prize for medicine: the full list of winners - The National - October 2nd, 2022 [October 2nd, 2022]
- The surprising link between circadian disruption and cancer may have to do with temperature - EurekAlert - October 2nd, 2022 [October 2nd, 2022]
- The global live cell imaging market is expected to grow at a CAGR of 8.44% during 2022-2027 - Yahoo Finance - October 2nd, 2022 [October 2nd, 2022]
- Chroma Medicine Announces Formation of Scientific Advisory Board of Global Experts in Gene Editing and Cell and Gene Therapy - PR Newswire - September 20th, 2022 [September 20th, 2022]
- Ring Therapeutics Announces Issuance of U.S. Patent for its Anellovector Compositions - Yahoo Finance - September 20th, 2022 [September 20th, 2022]
- Cholesterol gene mutation: Why would a healthy 27-year-old have severe heart problems? - 69News WFMZ-TV - September 20th, 2022 [September 20th, 2022]
- Gene Therapy for Severe Hemophilia B Could Be More Cost Effective Than Current Treatments - Managed Healthcare Executive - September 20th, 2022 [September 20th, 2022]
- AVROBIO Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration (FDA) for First Gene Therapy in Development for Cystinosis... - September 20th, 2022 [September 20th, 2022]
- The Biggest CGT Breakthroughs Through the Eyes of Our 2022 Power List - The Medicine Maker - September 20th, 2022 [September 20th, 2022]
- Leading Virus Researcher to Chair UVA's Department of Microbiology, Immunology and Cancer Biology - UVA Health Newsroom - September 20th, 2022 [September 20th, 2022]
- Work remains on Tay-Sachs and other Ashkenazi genetic disorders J. - The Jewish News of Northern California - September 20th, 2022 [September 20th, 2022]
- Study Shows Genetic Link to Moving to the Beat of Music - Newswise - September 20th, 2022 [September 20th, 2022]
- Viewpoint: In the post Roe v Wade world, what changes should a biology textbook writer make to address the medical repercussions of Dobbs? - Genetic... - September 20th, 2022 [September 20th, 2022]
- Alnylam Receives Approval in Europe for AMVUTTRA (vutrisiran) for the Treatment of Hereditary Transthyretin-mediated (hATTR) Amyloidosis in Adult... - September 20th, 2022 [September 20th, 2022]
- CSL flexes gene therapy muscle with latest drug - Sydney Morning Herald - September 20th, 2022 [September 20th, 2022]
- The MIT Press releases new book on the science of the heart from cardiac expert Dr. Sian Harding - EurekAlert - September 20th, 2022 [September 20th, 2022]
- Global Pharmaceutical Contract Manufacturing Market is projected to reach a market value of US$329.7 Billion in 2032: Visiongain Reports Ltd - Yahoo... - September 20th, 2022 [September 20th, 2022]
- Alzheon Reports Industry-Leading Biomarker, Brain Preservation and Clinical Effects Following 12 Months of Treatment in Phase 2 Trial of Oral ALZ-801... - September 20th, 2022 [September 20th, 2022]
- Do You Have Lung Cancer With An EGFR Mutation? If So, The Drug Tagrisso Might Be Right For You Based On New Results From A 'Practice Changing' Trial -... - September 20th, 2022 [September 20th, 2022]
- Getting rid of unwanted transformed cells: Possible new directions in cancer therapy - EurekAlert - September 20th, 2022 [September 20th, 2022]
- Sven Kili on reconvening with the ISCT - The Medicine Maker - September 14th, 2022 [September 14th, 2022]